査読有
doi：10.1159/000541082
PubMed No.：39265538
2023 Impact Factor：2.5
種類：原著
誌名：Oncology
発行年月：2024年9月
巻号頁：in press
論題：Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma
著者：Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Hiroyuki Suzuki, Hironori Koga, Ryoko Kuromatsu, Takumi Kawaguchi